ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Research Article
Revised

The effects of the glycaemic control on the severity of the delirium in the advanced phase of Alzheimer’s disease

[version 2; peer review: 2 approved]
PUBLISHED 28 Jul 2021
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

Background: Behavioral and psychological symptoms of dementia (BPSD) and delirium are common in advanced phases of Alzheimer’s disease (AD).
Methods: Thirty-eight moderate-severe AD patients were enrolled (n=16 affected by type 2 diabetes). Each patient received a comprehensive geriatric assessment (CGA) (including evaluation of BPSD and frailty), and a complete metabolic evaluation (including the measurement of the glycated hemoglobin, HbA1c).
Results: Both the hyper- and hypo-glycemic extremes of the glycemic spectrum worsened BPSD, but delirium was more susceptible to hypoglycemic events. The severity of delirium was significantly related to cognitive function (r = -0.585, p<0.001) and frailty (r = +0.440, p<0.05).
Conclusions: The measurement of HbA1c was useful for evaluating the risk of delirium in relationship to glycemic control and nutritional status.

Keywords

Marigliano-Cacciafesta-polypathology-scale, glycaemic control, Alzheimer’s disease, delirium

Revised Amendments from Version 1

This version of the article has details about the treatment with central nervous system agents in the groups of AD patients with and without diabetes. The references have been increased, considering the suggestions of the reviewers. The introduction and the discussion have been improved.

See the authors' detailed response to the review by Sandra Sigala
See the authors' detailed response to the review by Takahiko Nagamine

Introduction

Behavioral and psychological symptoms of dementia (BPSD) and delirium are common in the advanced phases of Alzheimer’s disease (AD) and worsen with disease severity, whereas symptoms of cognitive decline may be prevalent in the first phases of the disease1.

Both the hyper- and hypo-glycemic extremes of the glycemic spectrum may worsen cognitive functions in AD patients24, and nutrition plays an important role in the development of the delirium in frail older patients5.

The aim of this preliminary report was to evaluate the relationship between delirium and glycemic control in the advanced phases of AD.

Methods

Ethical statement

The study involved human participants with metabolic syndrome in aging and it was performed in accordance with the ethical standards of the local institutional committee (S. Andrea Hospital, ID number 67910) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent for participation and evaluation of data was obtained from the individual participants included in this study or from their caregivers, where ability to consent was affected by delirium.

Participants

We randomly (systematic sampling) enrolled 38 elderly patients (n = 11 males and n = 27 females) from the outpatients of the S. Andrea Hospital of Rome, in 2019. From their medical records, the patients met the criteria for probable AD dementia proposed by the National Institute on Aging-Alzheimer’s Association (NIA-AA)6 (Mini Mental State Examination (MMSE) score of 12.4+7.3, mean + standard deviation, in the moderate-severe stage of the disease). Prior to inclusion, subjects with other diseases, such as territorial infarction, intracranial hemorrhage, brain tumor, hydrocephalus, or severe white matter hyperintensities (WMH) were excluded from the study. Sixteen of the patients (16/38, 42% of the sample) were affected by type 2 diabetes (T2DM, according to 2020 American Diabetes Association, ADA, criteria)7, undergoing treatment with oral glucose lowering agents (n = 13, one patient with repaglinide) or with insulin (n = 3).

Assessments

Each patient received from our group: a) a comprehensive geriatric assessment (CGA), including the evaluation of the Activity of Daily Living (ADL), the Instrumental Activities of Daily Living (IADL), the Cumulative Illness Rating Scale (CIRS) and the Marigliano-Cacciafesta Polypathology Scale (MCPS)8,9; b) an anthropometric evaluation, including height, weight, body mass index (BMI), waist circumference, Mini Nutritional Assessment (MNA)10; c) a behavioral and psychological examination, using the Cornell’s scale, the Clinical Dementia Rating scale (CDR), the Neuropsychiatric Inventory (NPI) and the Confusion Assessment Method (CAM, with CAM-severity)1113. An assessment of glucose metabolism, including fasting glycaemia and insulinemia (excluded in insulin-treated patients), glycated haemoglobin (HbA1c) and insulin resistance by the means of the HOMA-index (glycemia mg/dl x insulinaemia µU/mol /405) (excluded in insulin-treated patients) and an evaluation of renal function, measuring creatinine and glomerular filtration rate (GFR) estimated using the Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI), was performed using a clinical chemistry analyzer (c16000 Architect System, Abbott Laboratories). A continuous glucose monitoring (FreeStyle Libre system) was used in selected patients with a high risk of hypoglycemic events, or with great variability of glycaemia during the day.

Statistical analysis

For the statistical analysis, carried out using Primer of Biostatistics Version 7, one-way analysis of variance (ANOVA) was used for the evaluation of the differences between the groups of patients. The relationship between two variables was examined by the means of regression analysis. A p<0.05 was assumed as significant. Data are presented as mean + standard deviation.

Results

The clinical characteristics of the 38 AD patients with and without T2DM are described in Table 114.

Table 1. Clinical characteristics in Alzheimer’s disease (AD) patients with (n = 16, females n = 9) and without (n = 22, females n = 18) type 2 diabetes (T2DM) (mean+standard deviation).

AD patients
without T2DM
AD patients
with T2DM
Age (years)83.3+5.782.3+4.2
MMSE11.6+7.112.7+7.5
ADL (IADL M and F)2.9+2.2 (M: 1.7+1.7; F: 1.2+1.8)2.7+1.8 (M: 1.4+1.5; F: 0.7+1.0)
MCPS48.6+10.547.4+7.0
CIRS-SI and -CI2.2+0.6 and 4.8+2.22.3+0.4 and 5.6+1.4
BMI24.4+7.026.7+5.7
Waist circumference (cm)M: 98.7+1.5; F: 90.3+22.6M: 97.7+8.6; F: 89.1+15.2
MNA17.4+6.018.8+4.8
Cornell14.2+8.611.4+6.0
CDR2.7+1.42.2+1.1
CAM2.7+1.52.2+1.9
CAM-S7.8+4.14.7+3.7*
NPI53.7+28.540.2+20.2
Fasting glycaemia (mg/dl)94.5+11.2135.6+58.0**
Fasting insulinaemia (µu/ml)6.0+2.68.9+9.5
HbA1c5.4+0.4%6.8+1.1%***
HOMA index1.4+0.63.2+3.4*
GFR (CKD-EPI; ml/min)66.0+16.964.9+23.4

MMSE, Mini Mental State Examination; ADL, Activity of Daily Living; IADL, Instrumental Activities of Daily Living; MCPS, Marigliano-Cacciafesta Polypathology Scale; CIRS, Cumulative Illness Rating Scale; SI, severity index; BMI, body mass index, MNA, Mini Nutritional Assessment; CDR, Clinical Dementia Rating scale; CAM, Confusion Assessment Method; CAM-S, CAM-severity; NPI, Neuropsychiatric Inventory; HbA1c, glycated haemoglobin; GFR, glomerular filtration rate; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration formula; M, male; F, female.

*p<0.05, **p<0.01, ***p<0.0001.

The percentage of use of drugs (antipsychotics, sleeping pills, antidepressants, antidementia, antiparkinsonian agents, mood stabilizing medications) in AD patients with or without diabetes, were respectively: 37%, 19%, 19%, 6%, 19%, 6%, and 32%, 18%, 23%, 9%, 9%, 9% (differences not significant). One AD patients with diabetes was treated with zolpidem.

The MMSE scores were inversely and significantly related to CAM-S score (r = -0.585, p<0.001), while MCPS scores were positively related to the CAM-S score (r = 0.440, p<0.05) (Figure 1a and 1b).

b4a9fe7b-c49c-4cfc-ac19-220bbf826545_figure1.gif

Figure 1.

a) The relationship between MMSE and CAM-S scores. b) The relationship between MCPS and CAM-S scores. MMSE, Mini Mental State Examination; CAM-S, Confusion Assessment Method-severity; MCPS, Marigliano-Cacciafesta Polypathology Scale.

The regression analysis between HbA1c and MMSE score showed a concave downward “” parabola (not significant) with apex at HbA1c of 10.5% and MMSE of 13.0. The regression analysis between HbA1c and the psychometric BPSD scales (Cornell, NPI and CAM-S) showed a “U” shape (concave upward parabola) (Cornell p<0.05, NPI<0.01 and CAM-S p<0.0001) (Figure 2). The apices of the parabolas were at HbA1c of 6.9%, 7.6% and 10.3%, the levels that minimized the Cornell, NPI and CAM-S scores, respectively (Figure 2). Therefore, the mean HbA1c that minimized all the behavioural disorders was 8.3%.

b4a9fe7b-c49c-4cfc-ac19-220bbf826545_figure2.gif

Figure 2. The relationship between the glycated haemoglobin (HbA1c) and the Neuropsychiatric Inventory (NPI), Cornell’s scale and Confusion Assessment Method-severity (CAM-S) score.

Continuous glucose monitoring in selected patients (n = 3) showed that, even if HbA1c level was within the normal range, either a great variability in glycaemia during the 24 hours or repeated hypo-glycemic events during the night (up to 26 hypoglycemic events in a single patient) were present (Figure 3).

b4a9fe7b-c49c-4cfc-ac19-220bbf826545_figure3.gif

Figure 3. Continuous glucose monitoring in selected cases (n=3).

A) Patient A, 81 years, MMSE=1.5, NPI=77, Cornell=13, CAM-S=17, HbA1c=6.6%, glucose mean 150 mg/dl, above/in/under the interval 56/43/1%, event of low glucose=0, mean duration=0, mean duration=0 min. B) Patient B, 77 years, MMSE=13.7, NPI=30, Cornell=12, CAM-S=4, HbA1c=5.5%, glucose mean 72 mg/dl, above/in/under the interval 0/16/84%, event of low glucose=26, mean duration=296 min. C) Patient C, 82 years, MMSE=10.5, NPI=52, Cornell=18, CAM-S=11, HbA1c=5.7%, glucose mean 94 mg/dl, above/in/under the interval 7/54/39%, event of low glucose=4, mean duration=281 min.

Discussion

In our preliminary study, polypathology and frailty was associated with the severity of delirium as demonstrated by using the MCPS scale in correlation with the CAM-S scale.

To the best of our knowledge this is the first report about the association of the MCPS and CAM-S scale, whereas the MCPS was previously evaluated by our group in patients with comorbidities and frailty9.

Glycemic control was associated with modification of BPSD and delirium in the advanced phases of AD. In particular, delirium (as indicated by the CAM-S score) was more susceptible to the glycemic control in its low range. As considered by point 7 (Metabolism and Nutritional state) of MCPS, high glucose levels increase the score of the MCPS scale (+25) only in conditions of diabetes mellitus decompensation, with significant risks of development of delirium.

Glycemic control modulated the appearance of BPSD and delirium with a polynomial U-shaped curve, with both the hyper- and hypo-glycemic extremes of the glycemic spectrum worsening BPSD. The regression equations showed that HbA1c levels between 6.9–10.3% (mean 8.3%) minimized BPSD, in agreement with International Diabetes Federation (2020)15 and ADA (2020)7 guidelines for managing T2DM in older people. As matter of fact, in healthy older subjects (with few coexisting chronic illnesses, intact cognitive and functional status) a reasonable HbA1c goal is <7.5% (with fasting or pre-prandial glucose of 90–130 mg/dl), whereas in complex/poor health patients (with more chronic illnesses, moderate-to severe cognitive impairment or >2 ADL dependencies) the reasonable HbA1c goal rises to <8.5 (with fasting or pre-prandial glucose of 100–180 mg/dl) to avoid possible overtreatment, hypoglycemic events and fall risk.

The HbA1c value of 6% corresponds to a mean glucose of 126 mg/dl, with 95% prediction limits of 100–152 mg/dl, which includes the lower goals for glycaemia (100–180 mg/dl) suggested by ADA standard of care1618 in older frail patients with moderate-severe dementia. More than half of our patients (22/38, 58%) showed HbA1c levels lower than 6%.

The reduction of one point (%) of HbA1c (from 6.8% to 5.8%) was associated with an increase of +2.2 points in Cornell, +7.0 points in NPI and +0.2 in CAM-S scores. Because of the parabolic profiles of the curves, another reduction of one point of HbA1c (from 5.8% to 4.8%) resulted in an exponential increase of BPSD scores (+5.6 Cornell, +14.4 NPI and +2.6 CAM-S).

The variability of glycaemia seemed to be associated with greater BPSD in AD patients, although it was not possible to carry out a statistical analysis because of the few number of patients in the sample (a limit of the study).

The treatment with central nervous system drugs (antipsychotics, sleeping pills, antidepressants, antidementia, antiparkinsonian agents, mood stabilizing medications) may be a confounding factor in AD patients1921, but, as above reported, no differences were found in the present study between the two AD groups with and without diabetes.

In conclusion, the measurement of HbA1c in elderly AD patients with advanced dementia (with and without T2DM) is recommended in order to evaluate glycemic control (and nutritional status). The reduction of mean glycemic levels (due to malnutrition in non-diabetic patients or overtreatment in diabetic patients) should be avoided by means of a multidimensional approach.

Data availability

DANS EASY: The Glycaemic Control and the Severity of the Delirium. https://doi.org/10.17026/dans-xq4-58fq14.

Data are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 16 Dec 2020
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Martocchia A, Scarienzi M, Prunas P et al. The effects of the glycaemic control on the severity of the delirium in the advanced phase of Alzheimer’s disease [version 2; peer review: 2 approved]. F1000Research 2021, 9:1470 (https://doi.org/10.12688/f1000research.26022.2)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 16 Dec 2020
Views
17
Cite
Reviewer Report 13 Jul 2021
Takahiko Nagamine, Director of Sunlight Brain Research Center, Hofu, Japan;  Department of Emergency Medicine, Matsumoto Surgical Hospital, Hofu, Japan 
Approved
VIEWS 17
This paper analyzes HbA1c (blood glucose control status) and delirium in patients with Alzheimer's disease. It is interesting to note that both high and low blood glucose levels increase the risk of delirium. The paper is clinically significant because it ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Nagamine T. Reviewer Report For: The effects of the glycaemic control on the severity of the delirium in the advanced phase of Alzheimer’s disease [version 2; peer review: 2 approved]. F1000Research 2021, 9:1470 (https://doi.org/10.5256/f1000research.28717.r89381)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 28 Jul 2021
    Antonio Martocchia, Sapienza University of Rome, ROMA CAPITALE, 00100, Italy
    28 Jul 2021
    Author Response
    Dear Prof Takahiko Nagamine,
    We agree with the evidence about HbA1c as a predictor of delirium in Alzheimer’s disease and with the interest about the effects of the presence/absence of diabetes ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 28 Jul 2021
    Antonio Martocchia, Sapienza University of Rome, ROMA CAPITALE, 00100, Italy
    28 Jul 2021
    Author Response
    Dear Prof Takahiko Nagamine,
    We agree with the evidence about HbA1c as a predictor of delirium in Alzheimer’s disease and with the interest about the effects of the presence/absence of diabetes ... Continue reading
Views
16
Cite
Reviewer Report 17 May 2021
Sandra Sigala, Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy 
Approved
VIEWS 16
The Ms entitled "The effects of the glycaemic control on the severity of the delirium in the advanced phase of Alzheimer’s disease" by Martocchia and coll is very interesting and gives support to the evidence that glycemic control in the ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Sigala S. Reviewer Report For: The effects of the glycaemic control on the severity of the delirium in the advanced phase of Alzheimer’s disease [version 2; peer review: 2 approved]. F1000Research 2021, 9:1470 (https://doi.org/10.5256/f1000research.28717.r85330)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 28 Jul 2021
    Antonio Martocchia, Sapienza University of Rome, ROMA CAPITALE, 00100, Italy
    28 Jul 2021
    Author Response
    Dear Reviewer Prof Sandra Sigala,
    We really appreciated your review, discussing the importance of a comprehensive clinical evaluation in frail elderly with Alzheimer’s disease.
    We agree that the limit of ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 28 Jul 2021
    Antonio Martocchia, Sapienza University of Rome, ROMA CAPITALE, 00100, Italy
    28 Jul 2021
    Author Response
    Dear Reviewer Prof Sandra Sigala,
    We really appreciated your review, discussing the importance of a comprehensive clinical evaluation in frail elderly with Alzheimer’s disease.
    We agree that the limit of ... Continue reading

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 16 Dec 2020
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.